PHARMAROTH LABS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | -.--% |
|
-.--% | -.--% |
| 2015 | PharmaRoth Labs, Inc. Receives Additional Order from Marcas de Renombre | CI |
| 2014 | PharmaRoth Labs, Inc. Announces New Distribution Agreement with Biotechnology Co., Ltd | CI |
Financials (USD)
| Sales 2009 | - | Sales 2010 | - | Capitalization | 5.74M |
|---|---|---|---|---|---|
| Net income 2009 | - | Net income 2010 | - | EV / Sales 2009 | - |
| Net Debt 2009 | 12.5K | Net Debt 2010 | 286K | EV / Sales 2010 | - |
| P/E ratio 2009 |
-777
x | P/E ratio 2010 |
-7.8
x | Employees | 2 |
| Yield 2009 * |
-
| Yield 2010 |
-
| Free-Float | 30.93% |
More Fundamentals
* Assessed data
More news
Current year
0.00
0.00
1 year
0.000.00
3 years
0.000.00
5 years
0.000.01
10 years
0.000.02
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 10-08-30 | |
Barry W. Hall
DFI | Director of Finance/CFO | 76 | 13-01-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 10-08-30 |
PharmaRoth Labs, Inc. is a nutraceutical company that is focused on the prevention and treatment of healthcare diabetes. The Company is engaged in the production, marketing, and distribution of Sucanon, a clinically-tested herbal-based nutraceutical treatment for type II diabetes. Sucanon is a medication that helps the body make better use of its own insulin, the hormone that controls blood sugar levels.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 390 | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- ROTH Stock
